Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Terminated 3Unknown 2Completed 2Active not recruiting 2Withdrawn 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Stomach Neoplasms 1Colorectal Neoplasms 1

Interventions

Cyclophosphamide 37Gemcitabine 31Paclitaxel 27Cisplatin 27Carboplatin 27Capecitabine 27camrelizumab 24Nivolumab 23apatinib 22Oxaliplatin 21fludarabine 20Radiotherapy 20toripalimab 17Immunotherapy, Adoptive 17Drug Therapy 17pembrolizumab 16Docetaxel 16Dexamethasone 15Bevacizumab 15N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 14Injections 14tislelizumab 13Temozolomide 13Rituximab 13Cetuximab 13Irinotecan 12130-nm albumin-bound paclitaxel 11anlotinib 10Fluorouracil 10Trastuzumab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Unknown × Alpelisib × Clear all
NCT04753203 2023-10-31

ALCAP

Korean Cancer Study Group

Phase 1/2 Unknown
65 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT04526470 2021-08-24

Alpelisib and Paclitaxel in PIK3CA-altered Gastric Cancer

Seoul National University Bundang Hospital

Phase 1/2 Unknown
55 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡